Deliver Your News to the World

Operitel Corporation Announces $50,000 Donation to the International Consortium on Anti-Virals


Peterborough ON., May 5th, 2008: Operitel Corporation, developer of the award winning LearnFlex™ learning management system, announced today a donation of $50,000 to the International Consortium on Anti-Virals (ICAV). Located in Peterborough, Ontario, with its headquarters at Trent University, ICAV is a not-for-profit drug development organization dedicated to the discovery, development and delivery of low-cost and accessible anti-viral drugs.

In January of 2007, Dr. Tom Phillips of the Greater Peterborough Innovation Cluster brought together two leading technology companies in the Peterborough region: Operitel Corporation and ICAV. Dr. Phillips understood that Operitel could accomplish the goals of knowledge distribution and management that ICAV requires to connect researchers around the globe. In concurrence with the Innovation Cluster’s mandate to support local business and continual growth within the Peterborough community, the connection was made between Operitel and ICAV to create a custom Microsoft Sharepoint® data management system.

“Operitel is very excited to be able to donate the Microsoft Sharepoint® platform and technical support to ICAV for their growing information technology needs. ICAV presented us with their need to establish a globally accessible information management solution for its members. ICAV is a perfect example of an organization that can fully utilize the solutions provided by Operitel and the SharePoint® platform,” said Michael Skinner, President and CEO of Operitel Corporation.

Microsoft’s SharePoint® platform provides a powerful, unified portal solution for organizations that need more efficient access to their information and to help their employees collaborate more effectively while delivering relevant content to partners and customers in a targeted and strategic way.

Key features of SharePoint® and key services Operitel will provide to provide ICAV include:
• Tools to increase the efficiency and accuracy of information exchanged in the development of much needed anti-viral treatments.
• A globally accessible document management solution for sharing and reviewing project documents.
• Connections between the people and workspaces of ICAV members internationally.
• Targeted and tailored information to ICAV’s users and groups.

“The complex challenge of providing a shared workspace to the more than 200 scientists in 24 countries that form the ICAV global network was presented to Operitel. ICAV needs a reliable and flexible information distribution and collaboration system. With this goal in mind, Operitel provided ICAV with a hosted solution built on the SharePoint® platform. “This information technology partnership will be a valuable asset for our information management requirements. ICAV is excited to be working with Operitel and will look forward to expanding our new portal to partners and network participants from around the world,” said Denis Ferkany, Director Corporate Strategy, ICAV.

About Operitel
Operitel Corporation, producer and distributor of the award winning LearnFlex™ Learning Management System, is an educational technology company that specializes in building adaptive web-based enterprise-level applications. Over the past six years, Operitel personnel have built and deployed applications for many clients in the high tech, financial, educational, and transportation sectors. Operitel is committed to supporting organizations in the acquisition, creation, and transfer of information and knowledge - the essential ingredients for success in a rapidly changing global economy. Operitel is located in Peterborough, Ontario, Canada. For more information on Operitel, please go to For more information on the LearnFlex™ learning management system, please go to

About ICAV
The International Consortium on Anti-Virals (ICAV) is a not-for-profit drug development organization dedicated to the discovery, development and delivery of anti-viral drugs for infectious and emerging viral diseases around the world. ICAV’s vision is global access to affordable anti-viral therapies for neglected and emerging viral diseases. ICAV is accelerating the development of anti-virals, targeting diseases such as pandemic influenza, HIV/AIDS, hepatitis, Dengue fever, rotavirus infection, and hemorrhagic fevers like Ebola and Marburg. For more information please visit

All terms, product and company names used in this document may be trademarks or registered trademarks o their respective owner’s, and are hereby acknowledged.


This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.